Inequitable Conduct Claim Nixed In Seroquel Suit

Law360, New York (July 2, 2008, 12:00 AM EDT) -- Sandoz Inc. and Teva Pharmaceutical Industries Ltd. have lost their bid to render the patent for AstraZeneca Pharmaceuticals LP's popular anti-psychotic drug Seroquel unenforceable, eliminating the need for a trial in the case.

Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey rejected all four arguments made by the generics makers to show that attorneys for AstraZeneca had engaged in inequitable conduct before the U.S. Patent and Trademark Office.

In an opinion issued Tuesday, Judge Pisano found that no material...
To view the full article, register now.